clinpharm.blogspot.com — Tysabri was withdrawn in February 2005 after two deaths because of PML . The Biogen Idec announced that no new cases of a PML (progressive multifocal leukoencephalopathy ) have been reported among patients taking Biogen Idec's multiple sclerosis drug Tysabri, since the FDA allowed it back into the market.
May 5, 2007 View in Crawl 4
No comments yet
It's quiet in here... can you hear the echo?